Nationwide Children’s-founded advanced pathology platform Deep Lens has now raised $17.5m in all as it looks to grow its business in the clinical trial recruitment segment.
Deep Lens, a US-based advanced pathology platform developer spun out of Nationwide Children’s Hospital, closed a $14m series A round led by venture capital firm Northpond Ventures yesterday.
Northpond was joined in the round by fellow VC firms Rev1 Ventures, Sierra Ventures and Tamarind Hill.
Founded in 2017, Deep Lens has created a digital imaging platform that exploits artificial intelligence (AI) to aid clinicians in studying the causes and effect of diseases, a branch of science known as advanced pathology.
In addition to pathological studies, Deep Lens’ platform – Virtual Imaging for Pathology Education and Research (Viper) – enables researchers to quickly identify patients suitable for clinical trials and can facilitate peer-to-peer project collaborations.
Deep Lens will use the cash for the further development of its platform and underlying AI technology. The money will also enable it to scale its service, sales and marketing operations to meet product demand, with a focus on the clinical trial recruitment segment.
Viper’s inventors include co-founder and chief executive Dave Billiter, who previously directed both the informatics team at Nationwide Children’s Biopathology Center and the informatics core at the hospital’s research institute.
Deep Lens has now raised $17.5m in funding altogether, it said, including $3.2m obtained in an October 2018 seed round led by Sierra Ventures that featured both Rev1 Ventures and Tamarind Hill.
